Courtney C, 2000, Lancet, 363, 2105
[AHA and NAC] Alzheimer's Association and the National Alliance for Caregiving. 1999. Who cares? Families caring for persons with Alzheimer's disease. Washington, DC.
[APA] American Psychiatric Association. 1994. Committee on nomenclature and statistics. Diagnostic and statistican manual of mental disorders, Revised Fourth Edition. Washington DC, APA.
Andersen CK, 2003, Scand J Public Health, 31, 119, 10.1080/14034940210134059
Baumgarten M, 1997, J Clin Epidemiol, 50, 1265, 10.1016/S0895-4356(97)00168-6
Beach DL., 1997, Gerontologist, 37, 233, 10.1093/geront/37.2.233
Becker R. 1991. Therapy of cognitive deficit in Alzheimer's disease: The cholinergic system. In: Becker R, Giacobini E (eds). Cholinergic basis for Alzheimer therapy. Boston, MA: Birhauser.
Beeri MS, 2002, Int J Geriatr Psychiatry, 17, 403, 10.1002/gps.490
Birks J, Harvey R. 2003. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev, 3:CD001190.
Blesa R., 2000, Dement Geriatr Cogn Disord, 11, 28, 10.1159/000051229
10.1001/archneur.59.11.1764
Brookmeyer R, 1998, Am J Public Health, 88, 1337, 10.2105/AJPH.88.9.1337
Bucks RS, 1996, Age Ageing, 25, 113, 10.1093/ageing/25.2.113
Burns A., 2000, Int J Neuropsychopharmacol, 3, 31, 10.1017/S1461145700001905
Callahan CM, 1995, Ann Intern Med, 122, 422, 10.7326/0003-4819-122-6-199503150-00004
Canadian Study of Health and Aging Working Group, 1994, CMAJ, 150, 899
Caro JJ, 2001, Neurology, 57, 964, 10.1212/WNL.57.6.964
Caro JJ, 2002, Dement Geriatr Cogn Disord, 14, 84, 10.1159/000064929
Carr DB, 1997, Am J Med, 103, 3S, 10.1016/S0002-9343(97)00262-3
[CDC and NCCDPHP] Centers for Disease Control and National Center for Chronic Disease Prevention and Health Promotion. 2000. Unrealized prevention opportunities: reducing the health and economic burden of chronic illness. Atlanta, GA, USA: US Department of Health and Human Services, Centers for Disease Control and Prevention.
Corey-Bloom J, 1998, Int J Geriatr Psychopharmacol, 1, 55
Cummings JL, 2002, JAMA, 287, 2335, 10.1001/jama.287.18.2335
Cummings JL, 2004, Am J Psychiatry, 161, 532, 10.1176/appi.ajp.161.3.532
DeJong R, 1989, Clin Ther, 11, 545
Doody RS, 2001, Neurology, 56, 1154, 10.1212/WNL.56.9.1154
Dunkin JJ, 1998, Neurology, 51, S53, 10.1212/WNL.51.1_Suppl_1.S53
Ernst R, 1994, Am J Public Health, 84, 1261, 10.2105/AJPH.84.8.1261
Ernst RL, 1997, Arch Neurol, 54, 687, 10.1001/archneur.1997.00550180013006
Ettner SL., 1995, Demography, 32, 63, 10.2307/2061897
Evans DA., 1990, Milbank Q, 68, 267, 10.2307/3350099
Farlow MR, 2001, Arch Neurol, 58, 417, 10.1001/archneur.58.3.417
Farrer LA, 1997, APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 278, 1349
Feldman H, 2003, J Am Geriatr Soc, 51, 737, 10.1046/j.1365-2389.2003.51260.x
Feldman H, 2004, Neurology, 63, 644, 10.1212/01.WNL.0000134663.79663.6E
Feldman H, 2001, Neurology, 57, 613, 10.1212/WNL.57.4.613
Fillit HM., 1999, Drug Benefit Trends, 1, 6
Fillit HM, 1999, Clin Ther, 21, 2173, 10.1016/S0149-2918(00)87246-X
Fillit HM 2000. The pharmacoeconomics of Alzheimer's disease. Am J Manag Care, 6(22 Suppl):S1139-44; discussion S1145-8.
Fillit HM, 2000, Int Psychogeriatr, 12, 389, 10.1017/S1041610200006499
Francois C, 2004, Clin Drug Invest, 24, 373, 10.2165/00044011-200424070-00001
Fratiglioni L, 1999, Drugs Aging, 15, 365, 10.2165/00002512-199915050-00004
10.1016/S0197-4580(00)82096-5
10.1001/archpsyc.55.9.809
Garfield FB, 2002, Pharmacoeconomics, 20, 629, 10.2165/00019053-200220090-00006
Gauthier S, 2002, Int Psychogeriatr, 14, 389, 10.1017/S104161020200858X
Getsios D, 2001, Neurology, 57, 972, 10.1212/WNL.57.6.972
Gutterman EM, 1999, J Am Geriatr Soc, 47, 1065, 10.1111/j.1532-5415.1999.tb05228.x
Hauber AB, 2000, Clin Ther, 22, 439, 10.1016/S0149-2918(00)89012-8
Hauber AB, 2000, Pharmacoeconomics, 17, 351, 10.2165/00019053-200017040-00005
10.1001/archneur.60.8.1119
Hepburn KW, 2003, Gerontologist, 43, 908, 10.1093/geront/43.6.908
Hill JW, 2002, Manag Care Interface, 15, 63
Huang LF, 1988, Public Health Reports, 103, 3
Hux MJ, 1998, CMAJ, 159, 457
Jones RW, 2004, Drugs Aging, 21, 607, 10.2165/00002512-200421090-00005
Kaufer DI, 2002, Am J Geriatr Psychiatry, 10, 84
Koppel R. 2002. Alzheimer's disease: the costs to U.S. businesses in 2002. Philadelphia, PA, USA: Alzheimer's Association.
Langa KM, 2001, J Gen Intern Med, 16, 770, 10.1111/j.1525-1497.2001.10123.x
Leon J, 1998, Health Affairs, 17, 206, 10.1377/hlthaff.17.6.206
10.1001/archneur.60.2.203
Marcusson J, 2003, Alzheimer Dis Assoc Disord, 17, S86, 10.1097/00002093-200307003-00005
Max W., 1996, Pharmacoeconomics, 9, 5, 10.2165/00019053-199609010-00002
Max W, 1995, J Aging Health, 7, 179, 10.1177/089826439500700202
McKhann G, 1984, Neurology, 34, 939, 10.1212/WNL.34.7.939
Meek P, McKeithan K, Schumock G. 1998. Economic considerations in Alzheimer's disease. Pharmacotherapy, 18(2 Pt 2):68-73; discussion 79-82.
Migliaccio-Walle K, 2003, Clin Ther, 25, 1806, 10.1016/S0149-2918(03)80171-6
Mittelman MS, 1996, JAMA, 276, 1725, 10.1001/jama.1996.03540210033030
Moore MJ, 2001, J Gerontol B Psychol Sci Soc Sci, 56, S219, 10.1093/geronb/56.4.S219
Morris JC, 1989, Neurology, 39, 1159, 10.1212/WNL.39.9.1159
Murman DL, 2002, Neurology, 59, 1721, 10.1212/01.WNL.0000036904.73393.E4
Murman DL, 2003, Neurology, 61, 944, 10.1212/WNL.61.7.944
Neumann PJ, 1999, Neurology, 52, 1138, 10.1212/WNL.52.6.1138
O'Brien BJ, 1999, J Am Geriatr Soc, 47, 570, 10.1111/j.1532-5415.1999.tb02572.x
Parnetti L, 1997, Drugs, 53, 752, 10.2165/00003495-199753050-00003
Raskind MA, 2000, Neurology, 54, 2261, 10.1212/WNL.54.12.2261
Rice DP, 1993, Health Aff (Millwood), 12, 164, 10.1377/hlthaff.12.2.164
Richards SS, 1999, Arch Intern Med, 159, 789, 10.1001/archinte.159.8.789
Rive B, 2004, Int J Geriatr Psychiatry, 19, 458, 10.1002/gps.1112
Rogers RL, 1990, J Am Geriatr Soc, 38, 123, 10.1111/j.1532-5415.1990.tb03472.x
Rosler M, 1999, BMJ, 318, 633, 10.1136/bmj.318.7184.633
10.1056/NEJM199704243361704
Sano M, 2003, Int J Geriatr Psychiatry, 18, 942, 10.1002/gps.1000
Small GW, 1998, Clin Ther, 20, 838, 10.1016/S0149-2918(98)80145-8
Small GW, 2002, J Am Geriatr Soc, 50, 321, 10.1046/j.1532-5415.2002.50065.x
Souetre E, 1999, Br J Psychiatry, 174, 51, 10.1192/bjp.174.1.51
Stern Y, 1997, JAMA, 277, 806, 10.1001/jama.1997.03540340040030
Stewart A, 1998, Int J Geriatr Psychiatry, 13, 445, 10.1002/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.0.CO;2-E
Stommel M, 1994, Gerontologist, 34, 199, 10.1093/geront/34.2.199
Stone R, 1987, Gerontologist, 27, 616, 10.1093/geront/27.5.616
Szafran RF., 2002, Monthly Labor Review, 125, 25
Tariot PN, 2000, Neurology, 54, 2269, 10.1212/WNL.54.12.2269
Taylor D, 2000, J Am Geriatr Soc, 48, 639, 10.1111/j.1532-5415.2000.tb04721.x
Teri L, 1997, Alzheimer Dis Assoc Disord, 11, 50
Teri L, 1994, Gerontologist, 34, 231, 10.1093/geront/34.2.231
Ward A, 2003, Int J Geriatr Psychiatry, 18, 740, 10.1002/gps.919
Wilcock G, 2003, Drugs Aging, 20, 777, 10.2165/00002512-200320100-00006
Wilcock GK, 2000, BMJ, 321, 1445, 10.1136/bmj.321.7274.1445
Wimo A, 1997, Int J Geriatr Psychiatry, 12, 841, 10.1002/(SICI)1099-1166(199708)12:8<841::AID-GPS652>3.0.CO;2-R
Wimo A, 1999, Int J Geriatr Psychiatry, 14, 338, 10.1002/(SICI)1099-1166(199905)14:5<338::AID-GPS909>3.0.CO;2-1
Wimo A, 2003, Pharmacoeconomics, 21, 327, 10.2165/00019053-200321050-00004
Winblad B. 2002. Socio-economic perspectives of dementia and costeffectiveness of treatment. 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, April 3-6, Geneva, Switzerland.
Winblad B, 2001, Neurology, 57, 489, 10.1212/WNL.57.3.489
Winblad B, 1999, Int J Geriatr Psychiatry, 14, 135, 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0
Zhu C, 2003, Rev Econ Household, 1, 59, 10.1023/A:1021899414829
